Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM4B | O94953 | 1/20 | 0.30 |
| ▸ | KDM5C | P41229 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13218216 | 0.81 | ALDH1A1 (0.36) | ALDH1A1LMNATSHRADORA2ASLC6A4 | |
| SCHEMBL15908749 | 0.73 | CHEK1 (0.33) | HPGDCHEK1PIM1AKT1FLT3 | |
| SCHEMBL594884 | 0.73 | DYRK1A (0.43) | ALDH1A1HPGDCHEK1LMNATSHR | |
| SCHEMBL398420 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL22547338 | 0.72 | ALDH1A1 (0.39) | ALDH1A1HPGDCHEK1PIM1AKT1 | |
| SCHEMBL398419 | 0.72 | PDE9A (0.37) | FLT3 | |
| SCHEMBL594883 | 0.71 | AURKA (0.41) | FLT3 | |
| SCHEMBL15264769 | 0.70 | BRD4 (0.42) | ALDH1A1HPGD | |
| SCHEMBL15141923 | 0.69 | PDE9A (0.49) | — | |
| SCHEMBL18168816 | 0.68 | BRD4 (0.32) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2022-02-03 | — | — | US | disclosed |
| US-10981915-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190308980-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10351571-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180339991-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| US-10000495-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000495-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2016109480-A1 | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | disclosed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | ALDH1A1 2470/4885HPGD 3174/4885CHEK1 2351/4885 |
| US-10981915-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | ALDH1A1 2470/4885HPGD 3174/4885CHEK1 2351/4885 |
| US-20190308980-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | ALDH1A1 2470/4885HPGD 3174/4885CHEK1 2351/4885 |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | ALDH1A1 2470/4885HPGD 3174/4885CHEK1 2351/4885 |
| US-20180339991-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | ALDH1A1 2470/4885HPGD 3174/4885CHEK1 2351/4885 |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | ALDH1A1 2470/4885HPGD 3174/4885CHEK1 2351/4885 |
| US-10351571-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | ALDH1A1 2470/4885HPGD 3174/4885CHEK1 2351/4885 |
| US-10000495-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | ALDH1A1 2470/4885HPGD 3174/4885CHEK1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.